POST-TEST

Hematologic Oncology Update — Issue 1, 2014

The c o rrec t answer is indicated with yellow highlightin g.

1. which of the following is true regarding the 6. a Phase II study of single-agent brentux- CRS related to CAR T-cell therapy? imab vedotin for the treatment of relapsed a. It manifests as fever, nausea, myalgia or refractory CD30-positive non-Hodgkin and hypotension lymphomas demonstrated promising antitumor b. It is associated with high levels of IL-6 activity in patients with DLBCL with a broad c. It is irreversible range of CD30 expression levels. d. Both a and b a. True b. False 2. Updated results of a pilot trial by Porter and colleagues of chimeric antigen receptor T-cell 7. results from a Phase II trial comparing therapy for patients with relapsed/refractory consolidation therapy with a single dose of CLL reported an overall response rate of 90Y-ibritumomab tiuxetan to rituximab mainte- ______. nance for patients with newly diagnosed FL a. 12% who have experienced a response to R-CHOP b. 57% demonstrated statistically significant differ- ences in ______favoring rituximab c. 82% maintenance. 3. Tocilizumab, an IL-6 receptor antagonist, is a. Progression-free survival effective at reversing the cytokine release b. Overall survival syndrome associated with chimeric antigen c. Both a and b receptor-modified T-cell therapy. a. True 8. The final Stage II results of the Phase b. False III CLL11 trial for patients with CLL and coexisting medical conditions demon- 4. The results of a Phase III study of induction strated that obinutuzumab/chlorambucil was therapy with lenalidomide and dexametha- superior to rituximab/chlorambucil in terms of sone followed by maintenance lenalidomide ______. for patients with high-risk SMM demonstrated a. Progression-free survival a statistically significant improvement in b. Overall response rate ______versus observation only. c. Both a and b a. Time to disease progression b. Three-year OS rate 9. Based on the results of a study by Yilmaz c. Five-year OS rate and colleagues, long-term treatment with ______may result in a significant d. All of the above decline in the glomerular filtration rate in 5. The ongoing Phase III ECOG-E3A06 trial is patients with CML. evaluating ______versus observation a. Dasatinib alone for patients with asymptomatic high-risk b. Imatinib SMM. c. Nilotinib a. Lenalidomide b. Lenalidomide in combination with 10. ______is an FDA-approved potent TKI low-dose dexamethasone for the treatment of chronic myeloid leukemia that was temporarily suspended because of a c. Lenalidomide in combination with high- risk of serious thrombosis and stenosis. dose dexamethasone a. Ponatinib b. Bosutinib c. Dasatinib d. Omacetaxine mepesuccinate e. All of the above